Skip to main content
OpenTrials
Completed

NCT Number: NCT00883870

Mesenchymal Stem Cells in Critical Limb Ischemia

This clinical trial aims to study the safety and efficacy of adult mesenchymal stem cells in critical limb ischemia.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Bhagawan Mahaveer Jain Heart Centre, Bangalore, Karnataka, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or females with non-child bearing potential in the age group of 18-60 yrs of Indian origin.
  • Established CLI, clinically and hemodynamically confirmed as per Rutherford- II-4, III-5, or III-6; Patients having Infra-inguinal arterial occlusive disease with rest pain or ischemic ulcer/necrosis, who are not eligible for or have failed traditional revascularization treatment (No option patients)
  • Ankle Brachial Pressure Index (ABPI) ≤ 0.6 or ankle pressure ≤ 70 mm Hg or TcPO2 ≤ 60 mmHg in the foot
  • Patients if having associated Type II Diabetes, should be on medication and well controlled (HbA1c ≤ 8%) without complications
  • Patients who are able to understand the requirements of the study, and willing to provide voluntary written informed consent, abide by the study requirements, and agree to return for required follow-up visits
  • Normal liver and renal function
  • On regular medication for hypertension if any

Exclusion criteria

  • Patients with CLI suitable for surgical or percutaneous revascularization as determined by the surgeon performing vascular procedure and patients with any acute/chronic inflammatory condition
  • CLI patient requiring amputation proximal to trans-metatarsal level
  • Patients with gait disturbance for reasons other than CLI.
  • Type I diabetes
  • Patients having respiratory complications/left ventricular ejection fraction < 25%f) Stroke or myocardial infarction within last 3 months
  • Patients who are contraindicated for MRA
  • Have clinically serious and/or unstable inter-current infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy
  • Documented terminal illness or cancer or any concomitant disease process with a life expectancy of less than 1 year
  • Patients already enrolled in another investigational drug trial or completed within 3 months.
  • History of severe alcohol or drug abuse within 3 months of screening.
  • Hb% < 10 gm%, Serum Creatinine ≥ 2mg%, Serum Total Bilirubin ≥2mg%, HbA1c > 8%
  • Women with child bearing potential, pregnant and lactating women.
  • Patients tested positive for HIV 1, HCV, HBV,

Treatment and study plan

Mesenchymal Stem Cells

Drug

Intramuscular injection

Plasmalyte A

Drug

Intramuscular injection

Primary outcomes

  1. AE and symptomatic relief

    Time frame: 6 months

Secondary outcomes

  1. Increase in transcutaneous partial oxygen pressure (TcPO2) and Ankle brachial pressure index (ABPI) - measured by Doppler

    Time frame: 6 months

Sponsors and collaborators

Lead sponsor

Stempeutics Research Pvt Ltd

Industry

Registry information

Official study title

A Randomized, Double Blind, Multicentric, Placebo Controlled, Single Dose, Phase - i/ii Study Assessing the Safety and Efficacy of Intramuscular ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cells in Patients With Critical Limb Ischemia (Cli)

Important dates

Study start
2009
Primary completion
2010
Study completion
2012
First posted
Apr 20, 2009
Registry last updated
Mar 5, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.